An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
Background: Vilazodone, a novel selective serotonin reuptake inhibitor and 5-HT1A partial agonist, was approved in 2011 for treatment for major depression. We aimed to compare the efficacy and safety of vilazodone versus escitalopram in patients with major depression at 4 weeks. Methods: Participant...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-01-01
|
| Series: | Indian Journal of Psychological Medicine |
| Online Access: | https://doi.org/10.1177/02537176221127162 |